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Abstract: Ergot alkaloids, in their active isomeric form, affect animal health and performance,
and adsorbents are used to mitigate toxicities by reducing bioavailability. Adsorbents with high
specificity (molecularly imprinted polymers: MIP) adsorb ergot alkaloids in vitro, but require
evaluation for biological implications. Using ex vivo myography, synthetic polymers were evaluated
for effects on the bioactivity of ergotamine tartrate (ETA). Polymers were first evaluated using
isotherms. Lateral saphenous veins were collected from 17 steers for four independent studies:
dose response of ETA, adsorbent dose response, validation of pre-myograph incubation conditions
and MIP/ non-molecularly imprinted polymer (NIP) comparison. Norepinephrine normalized
percent contractile response to increasing ETA exhibited a sigmoidal dose response (max: 88.47 and
log of the effective molar concentration (EC50 ) (−log [ETA]) of 6.66 ± 0.17 M). Although sample
preparation time affected contractile response (p < 0.001), pre-myograph incubation temperature
(39 vs. 21 ◦ C, 1 h) had no effect (p > 0.05). Isothermal adsorption showed a maximum adsorption
of 3.27E-008 moles·mg−1 and affinity between 0.51 and 0.57 mg (R2 : 0.83–0.92) for both polymers,
with no significant difference between polymers (p > 0.05). No significant differences in maximum
inhibitory (p = 0.96) and IC50 responses (p = 0.163) between MIP and NIP were noticed. Normalized
percent contraction could be predicted from the in vitro adsorption data (R2 = 0.87, p < 0.01), for
both polymers. These studies indicate that synthetic polymers are potentially effective adsorbents
to mitigate ergot toxicity caused by ergot alkaloids, with little evidence of significant differences
between MIP and NIP in aqueous media.
Keywords: ergot alkaloids; myograph; imprinted polymer
Key Contribution: Synthetic polymers were shown to effectively adsorb the ergot alkaloid;
ergotamine; from solution; resulting in decreased ex vivo vasoconstriction in bovine blood vessels.
Results indicate potential for use of synthetic polymers as feed additives for livestock to ameliorate
dietary alkaloid-related toxicities.

1. Introduction
Alkaloids produced by the endophytic fungus Epichloë coenophiala are known to produce complex
biological responses in animals due to agonistic and antagonistic interactions with biogenic amine
receptors [1]. Ergot alkaloids can induce strong and prolonged vasoconstriction in human coronary
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and temporal arteries [2], in canine saphenous and femoral veins [3], and in arterial preparations
from rats and guinea pigs [4]. Myographic studies using several ergot derivatives have confirmed the
vasoconstrictive effects in bovine preparations of lateral saphenous veins [5], right ruminal arteries
and veins [6], and mesenteric arteries and veins [7]. Studies have also established interactions between
ergot alkaloids and neurotransmitter receptors, indicating the structural similarities between the
alkaloids and biogenic amines (neuro-hormones), like serotonin [8,9], norepinephrine [10,11] and
dopamine [12,13], as a cause for vasoconstriction. Additionally, among two structural classes of
ergot alkaloids, ergopeptides (e.g., ergotamine, ergocornine, ergocryptine and ergocristine) are known
to produce more persistent dose dependent vasoconstriction, while ergolines (e.g., ergonovine and
lysergic acid) produce rapid, but less intense and less persistent, contractile responses [14].
Ergot alkaloids contain a C9=C10 double bond that can readily epimerize with respect to
the stereogenic center at C-8, especially in the presence of alkalis, forming a series of right-hand
rotation (S)-isomers representing isolysergic acid derivatives [15]. The C-8 epimers differ in biological
and physicochemical properties and have different pKa values [16,17]. Studies have shown that
C-8-(R) isomers (-ines) are biologically active, while the C-8-(S) isomers (-inines) are inactive [1,18].
The conversion of -ines to -inines is rapid, especially in aqueous acidic or alkaline solutions [15] and
the -inines are likely to be reactivated to their biologically active -ine form [19]. Studies have shown
that ergopeptinines can also convert back into the -ine form, especially in methanol, aqueous organic
solvents and acids [20]. Additionally, ergot alkaloids are sensitive to light [15,21] and heat [22,23],
which leads to both isomerization and degradation. Because epimerization influences biological
activity, when evaluating remediation approaches, the use of bioassays may provide information that
would not be available from simple quantification of alkaloid concentrations.
Researchers have evaluated the application of toxin adsorbents, including esterified
glucomannans, commercially available clay-based products [24] and yeast cell wall based products
(FEB-200TM : [25]), to alleviate the negative effects of endophyte toxins, and have indicated a reduction
in the bioavailability of toxins in the gastrointestinal tract (GIT). In recent years, adsorbents synthesized
using molecular imprinting technologies have gained importance due to specific binding through
selective recognition. Molecular imprinting is a technique for synthesizing macromolecular polymers
with multi-functional receptor groups that aid in specific interaction with a targeted molecule [26–28].
Generally, molecularly imprinted polymers (MIP) are synthesized using functional monomers,
cross-linkers, an initiator and porogen in the presence of an adsorbate of interest, called a template.
The template interacts with functional monomers during polymerization, which are then networked
with cross-linkers to form polymers of larger molecular weight (generally > 1000 kDa, depending on
the monomer type) [29,30]. These polymers are then washed to remove the template, thereby creating
heterogeneous binding sites with functional groups arranged in geometries capable of binding the
template and similar molecules with varying affinities [31]. Because of specific molecular recognition
properties, MIPs have been applied as sorbent materials for sample clean-up in analytical chemistry [32]
and as sensors in biomedical applications [33]. However, to date, there have been no studies with the
application of synthetic polymers as toxin adsorbents in animal feed.
Ergovaline is the predominant alkaloid in naturally contaminated tall fescue and is found
in the range of 0.5 to 5 mg·kg−1 [34]. Studies have suggested that ergotamine concentrations in
contaminated forage and seeds are generally found at a rate of 0–12 and 15–40 percent of ergopeptides,
respectively [35,36]. Levels of total ergopeptides in surveys of rye have been reported at over
7 mg·kg−1 [37], with ergotamine as the major alkaloid. These studies suggest that ergotamine is
comparatively greater in Clavicep infection (rye) while ergovaline is in greater concentrations in
Epichloë infection (tall fescue).
To understand how best to use adsorbents to help mitigate ergot alkaloid toxicity, the effects
must be studied in a biological system. The kinetics of adsorbent-adsorbate interactions are
profoundly influenced by the equilibrium conditions. The in vitro efficacy of adsorbents may be
erroneously interpreted with respect to their biological implications, due to the simplified nature of
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in vitro experimental models, without encountering biological events that could change the efficacy,
and also without accountability for isomeric forms and external factors that influence biological
responses. Therefore, as a complement to in vitro studies, ex vivo bioassays have been used as
means to bridge the gap between in vitro studies and complex in vivo experiments. The interactions
between ergot alkaloids and neurotransmitters has been extensively studied using myograph-based
techniques [5,6,38,39]. Myographic bioassays are based on the contractile response of smooth muscle
present in blood vessels. Ergotamine and ergovaline have been shown to produce dose dependent
smooth muscle contraction of blood vessels [5].
In vitro isothermal adsorption studies are commonly used to evaluate adsorbents for their
adsorption efficiency. However, the biological implications of in vitro adsorption studies need to be
established and the understanding of consequences of alkaloid epimerization during the experimental
procedures in the presence of polymers has to be assessed. To aid understanding of the biological
implications of adsorbing dietary alkaloids with a synthetic, molecularly-imprinted polymer, our
main objective was to determine the extent to which the ex vivo myographic response to ergotamine
in the presence of polymers would correspond to predictions from isothermal adsorption studies.
Ergotamine tartrate was used as a template molecule because it is a commercially available molecule
with stereochemistry that is representative of the ergot peptide family, and also because of the
existence of well-established analytical methods for quantification [18,37]. Previously synthesized and
characterized MIP and corresponding non-molecularly imprinted polymer (NIP) [40,41] were used
as adsorbents.
2. Results
Prior to evaluating the ability of polymers to mitigate the physiological effects of ergotamine
tartrate (ETA), we conducted a series of experiments to establish (1) the myographic dose response to
ETA, and (2) the proper incubation conditions for the evaluation of polymer effects.
2.1. Dose Response to ETA
The contractile response of lateral saphenous vein cross sections to logarithmically increasing
concentrations of ETA was described by a sigmoidal relationship (R2 = 0.95; Figure 1; Table 1). The
relationship was linear between 9.766 × 10−8 and 6.250 × 10−6 M ETA, and the maximum contractile
response of 88% was observed at and above 3.125E-06 M ETA. The effective molar concentration (EC50 )
of ETA that produced 50 percent of the norepinephrine (NE)-normalized contractile response in terms
of −log [ETA] was 6.66 ± 0.17 (2.26 × 10−7 M). The results were comparable to −log EC50 values of
6.48 ± 0.38 M obtained for mesenteric veins from steers fed endophyte free tall fescue seeds, when
exposed to ETA [7]. Although the range of ETA concentrations used to construct the dose response
curve may have exceeded levels expected to be physiologically relevant, these concentrations were
appropriate for achieving saturation of receptor-agonist interactions to allow accurate calculation of
the EC50 .
Table 1. Dose response parameters for norepinephrine normalized contractile response of saphenous
vein smooth muscle to increasing concentrations of ergotamine tartrate (ETA).

1

Dose Response Parameters 1

Mean

95% Confidence Interval

Minimum contractile response, %
Maximum contractile response, %
Log EC50 , −Log [ETA]
Goodness of fit
Degrees of freedom
R square

5.7
88.5
6.66

−13.9 to 25.4
80.8 to 96.1
6.32 to 7.01

9
0.95

Experiments were carried out with twelve increasing concentrations of ETA as a single dose exposure to each
blood vessel section in individual myograph chambers (n = 10). Percent contraction (NE normalized) = 88.5 + (5.7 −
88.5)/(1 + 106.664−intital [ETA] ) (Equation (3), Section 5.7). EC50 , effective molar concentration; NE, norepinephrine.

Toxins
2018,
10,10,
58 x FOR PEER REVIEW
Toxins
2018,

4 of
1616
4 of

Figure
1. 1.
Norepinephrine
normalized
contractile
response
curve
ofof
smooth
muscle
(lateral
saphenous
Figure
Norepinephrine
normalized
contractile
response
curve
smooth
muscle
(lateral
saphenous
vein)
to
increasing
concentrations
of
ETA.
The
points
are
means
and
the
vertical
bars
show
vein) to increasing concentrations of ETA. The points are means and the vertical bars show
the the
SEM
6.664
−
intital
[ETA] ))
SEM
= 10).
Percent
contraction
normalized)
− 88.5)/(1
+ 10 [ETA])) (Equation
(n =(n10).
Percent
contraction
(NE (NE
normalized)
= 88.5= +88.5
((5.7+ −((5.7
88.5)/(1
+ 106.664−intital
3,
(Equation
(3), Section 5.7).
Section 5.7).

2.2.
2.2.Validation
ValidationStudies
Studies
The
polymers
additional
before
myographic
Theevaluation
evaluationofofthe
the
polymersintroduced
introducedanan
additionalpreparatory
preparatorystep
step
before
myographic
analysis,
namely
Thus,
we
conducted
experiments
toto
evaluate
analysis,
namelythe
theincubation
incubationofofpolymers
polymerswith
withETA.
ETA.
Thus,
we
conducted
experiments
evaluate
the
potential
influence
of conditions
associated
with with
this incubation
on theon
contractile
response
of bloodof
the
potential
influence
of conditions
associated
this incubation
the contractile
response
vessels.
a feedIn
additive
polymers polymers
would be exposed
toexposed
alkaloidstowithin
the GI
tract of
blood In
vessels.
a feed application,
additive application,
would be
alkaloids
within
theanGI
◦ C. Thus, we compared incubation at typical room temperature
animal,
a temperature
around 39 of
tract ofatan
animal, at a of
temperature
around 39 °C. Thus, we compared incubation at typical room
◦ C) with incubation
◦ C. Additionally,
(21
at 39
recognizedwe
that
the incubation
time
could result
temperature
(21 °C) with
incubation
at 39 °C. we
Additionally,
recognized
that the
incubation
time
incould
substantial
differences
in differences
adsorption,inand
that theseand
effects
interactmight
with interact
the incubation
result in
substantial
adsorption,
that might
these effects
with the
temperature.
Thus, we constructed
2 × 2 factorial
structure
to evaluate
each
incubation temperature.
Thus, wea constructed
a 2treatment
× 2 factorial
treatment
structure
to combination
evaluate each
ofcombination
these two incubation
andtemperatures
two incubation
min and 60
min).
indicated
of these temperatures
two incubation
andtimes
two (2
incubation
times
(2Results
min and
60 min).
that
an incubation
period
of 60 min
to of
myographic
evaluation
reduced
(p < 0.001)
the
Results
indicated time
that an
incubation
timeprior
period
60 min prior
to myographic
evaluation
reduced
contractile
compared
to a compared
2-min incubation
period,
whenperiod,
ETA solution
wassolution
incubated
(p < 0.001)response,
the contractile
response,
to a 2-min
incubation
when ETA
was
◦
◦
either
at 21 either
C or 39
C, °C
with
(p interaction
= 0.26) between
incubation
time
and temperature.
incubated
at 21
orno
39interaction
°C, with no
(p = 0.26)
between
incubation
time and
Additionally,
was no significant
(p > 0.05)
in contractile
response
due toresponse
incubation
temperature.there
Additionally,
there wasdifference
no significant
difference
(p > 0.05)
in contractile
due
temperature
(Figure
2). The standard
evaluation
protocol
included
60 minincluded
of incubation
to incubation
temperature
(Figure 2).adsorption
The standard
adsorption
evaluation
protocol
60 min
and
min of centrifugation.
reduce the potential
time effect
associated
with
centrifugation,
an
of 30
incubation
and 30 min ofTocentrifugation.
To reduce
the potential
time
effect
associated with
alternate
protocolan
was
evaluated,
in which
centrifugation
period
30 min (25,000
g, 39 ◦of
C)30
used
centrifugation,
alternate
protocol
wasthe
evaluated,
in which
the of
centrifugation
period
min
to(25,000
separate
ETA wasbound
replaced
with
fitted
g, bound
39 °C) and
usedfree
to separate
and
freefiltration
ETA was(polypropylene
replaced with filtration
filtration columns
(polypropylene
with
quartzcolumns
frits). Before
new
protocol,
non-specific
binding
of ETA onnon-specific
filtration
filtration
fittedimplementing
with quartz the
frits).
Before
implementing
the
new protocol,
columns
evaluated.
There columns
was no significant
difference
(p =was
0.87)
myographic
response(pbetween
bindingwas
of ETA
on filtration
was evaluated.
There
noinsignificant
difference
= 0.87) in
−
7
−7
the
ETA treatment
(7.813between
× 10 M)
filtered through
and the
control
myographic
response
thethat
ETAwas
treatment
(7.813 × the
10 filtration
M) that column
was filtered
through
the
(without
filtration;
It was observed
that the myographic
decreased
filtrationcolumn
column
and the Figure
control3).(without
column filtration;
Figure 3). Itresponse
was observed
thatby
the
◦ C vs.
◦ C)min
response
decreased
by 25
percent
thetemperature
incubation (21
period
was
at each
25myographic
percent when
the incubation
period
was
60 minwhen
at each
39 60
at similar
temperature
(21 °C vs. 39 °C) at similar ETA concentrations.
ETA
concentrations.

Toxins 2018, 10, 58
x FOR PEER REVIEW
Toxins 2018, 10, x FOR PEER REVIEW

of 16
16
55 of
5 of 16

Figure
of incubation
temperature
and length
of incubation
in buffer
ETA (7.813
×
Figure 2.2.Effect
Effect
of incubation
temperature
and length
of incubation
in containing
buffer containing
ETA
Figure
Effect
of
incubation
temperature
and lengthveins.
of incubation
in buffer
containing
ETA (7.813
×
−7 M) 2.
−
7
10
on
the
contractile
response
of
saphenous
Each
data
point
was
the
mean
of
six
(7.813
× 10 M) on the contractile response of saphenous veins. Each data point was the mean
−7
10 M) on oftheblood
contractile
response
of saphenous
veins.
Each
data point
was the
mean of six
replications
vessels
± SEM.
Incubation
timetime
(60 (60
min)
reduced
(p(p< <0.001)
of six replications
of blood
vessels
± SEM.
Incubation
min)
reduced
0.001)the
the contractile
contractile
replications
of
blood
vessels
±
SEM.
Incubation
time
(60
min)
reduced
(p
<
0.001)
the
contractile
response
response and
and there
there was
was no
no effect
effect (p
(p >> 0.05)
0.05) of
oftemperature
temperature or
or interaction
interaction between
between incubation
incubation time
time and
and
response
and
there
was
no
effect
(p
>
0.05)
of
temperature
or
interaction
between
incubation
time
and
temperature
(p
=
0.26).
Different
letters
(a,b)
above
columns
denote
significant
differences
(p
<
0.001)
temperature (p = 0.26). Different letters (a,b) above columns denote significant differences (p < 0.001)
temperature
(p
=
0.26).
Different
letters
(a,b)
above
columns
denote
significant
differences
(p
<
0.001)
between
between incubation
incubation times.
times.
between incubation times.

Figure 3. The contractile response of lateral saphenous veins exposed to ETA treatment
(7.813 × 10−7 M) that were filtered through polypropylene filtration columns fitted with quartz frits,
−7
at 39 ◦ C.
data pointresponse
represents
six replications
of blood to
vessels
± SEM. There
Figure
3. Each
The contractile
of mean
lateralof
saphenous
veins exposed
ETA treatment
(7.813was
× 10no
−7
Figure
3.
The
contractile
response
of
lateral
saphenous
veins
exposed
to
ETA
treatment
(7.813
×
10
significant
difference
(p = 0.8752)
in response filtration
between the
filtration
and
no filtration
methods.
Similar
M)
that were
filtered through
polypropylene
columns
fitted
with
quartz frits,
at 39 °C.
Each
M) that
filtered
through
filtration
columns
with
quartz
frits,no
at significant
39 °C. Each
letters
(a)were
above
columns
denote
lackreplications
of significant
(p >fitted
0.05)
between
columns.
data
point
represents
mean
ofpolypropylene
six
of difference
blood
vessels
± SEM.
There
was
data
point
represents
mean
of
six
replications
of
blood
vessels
±
SEM.
There
was
no
difference (p = 0.8752) in response between the filtration and no filtration methods. Similar significant
letters (a)
difference
(p = denote
0.8752)
in response
between
the
filtration
andbetween
no filtration
methods. Similar letters (a)
2.3. Polymer
Evaluation:
Isothermal
Adsorption
Studies
above
columns
lack
of significant
difference
(p > 0.05)
columns.
above columns denote lack of significant difference (p > 0.05) between columns.

The isothermal adsorption properties of polymers to ETA in modified Krebs-Henseleit buffer
2.3. Polymer Evaluation: Isothermal Adsorption Studies
were
evaluated.
The proportional
of ETA
adsorbed on the polymers with different inclusion
2.3. Polymer
Evaluation:
Isothermal amount
Adsorption
Studies
isothermal
polymers
to ETA in
modified derived
Krebs-Henseleit
buffer
ratesThe
of MIP
and NIPadsorption
are shownproperties
in Figure 4,ofand
the adsorption
parameters
from a one-site
The isothermal
adsorption properties
of
polymers
to on
ETA
inpolymers
modifiedwith
Krebs-Henseleit
buffer
2
were
evaluated.
The
proportional
amount
of
ETA
adsorbed
the
different
inclusion
total binding curve are included in Table 2. The goodness of fit (R ) was better for MIP (0.93) compared
wereofevaluated.
The
ofand
ETAthe
adsorbed
on the
polymersderived
with differenta inclusion
rates
MIP and
NIP proportional
are ETA
shown
inamount
Figure(B4,
adsorption
parameters
one-site
to NIP
(0.84).
Maximum
adsorption
when the
polymer inclusionfrom
rate exceeded
max ) occurred
rates
of
MIP
and
NIP
are
shown
in
Figure
4,
and
the
adsorption
parameters
derived
from
a one-site
2
total
are included
inand
Table
The
goodness
of fit
(R ) was
bettertypes.
for
MIP
(0.93)
5 mg binding
in 10 mLcurve
of incubation
media,
did2.not
differ
(p = 0.78)
between
polymer
Similarly,
total binding
curve
areMaximum
included ETA
in Table
2. The(Bgoodness
of fit
(R2) the
waspolymer
better for
MIP (0.93)
compared
to
NIP
(0.84).
adsorption
max
)
occurred
when
inclusion
neither dissociation constants (Kd ), nor slopes of nonspecific binding (NS), differed between MIP rate
and
compared5 to
(0.84).
ETA
adsorption
(Bmax
) occurred
polymer
inclusion
rate
exceeded
mgNIP
in 10
mL Maximum
of incubation
media,
and did
not
differ (p when
= 0.78)the
between
polymer
types.
NIP (p ≥ 0.80).
exceeded
5
mg
in
10
mL
of
incubation
media,
and
did
not
differ
(p
=
0.78)
between
polymer
types.
Similarly, neither dissociation constants (Kd), nor slopes of nonspecific binding (NS), differed between
Similarly,
neither
dissociation constants (Kd), nor slopes of nonspecific binding (NS), differed between
MIP
and NIP
(p ≥ 0.80).
MIP and NIP (p ≥ 0.80).

Toxins
2018,
10, 10,
58 x FOR PEER REVIEW
Toxins
2018,

6 of
16 16
6 of

Figure
Ergotamine adsorption
adsorption ofof polymers
polymers(molecularly
(molecularlyimprinted
imprinted
polymers,
Figure4. 4. Ergotamine
polymers,
MIPMIP
andand
nonnon-molecularly
imprintedpolymer,
polymer,NIP),
NIP),in
in modified
modified Krebs–Henseleit
binding
molecularly imprinted
Krebs–Henseleit buffer
buffermedia
mediafitted
fittedtoto
binding
saturation
curve
with
specific
binding
sites.
saturation
curve
with
specific
binding
sites.
Table
2. Adsorption
parameters
with
polymer
to to
ETA
in in
modified
Krebs-Henseleit
buffer
media
at at
Table
2. Adsorption
parameters
with
polymer
ETA
modified
Krebs-Henseleit
buffer
media
◦ C (n = 10).
3939
°C (n = 10).
MIPMIP

NIPNIP

p-Value
p-Value

1
1
−810
Bmax
(Moles)
×810
± 2.391
± 3.877
0.78
0.78
Bmax
(Moles)
3.273.27
× 10−
± −8
2.391
× 10−×9 10−9
3.153.15
× 10×
±−83.877
× 10−×9 10−9
2
2
0.510.51
± 0.108
0.570.57
± 0.193
0.80
KK
of polymer)
d d(mg
(mg
of polymer)
± 0.108
± 0.193
0.80
0.81
NS (Moles mg−1 ) 3 −1 3 −2.06 × 10−10 ±−102.361 × 10−10 −10 −9.63 × 10−11 ±
× 10−10 −10
−113.776
NS (Moles
mg
)
−2.06
×
10
±
2.361
×
10
−9.63
×
10
±
3.776
×
10
0.81
0.927
0.835
R2
R2
0.927
1 B
2 K 0.835
max is the maximum specific adsorption of ETA in moles at equilibrium.
d is the equilibrium adsorption
1 Bmax is the maximum specific adsorption of ETA in moles
2 Kd is the equilibrium
at is
equilibrium.
constant
(polymer needed to achieve a half-maximum adsorption). 3 NS
the slope of nonspecific
adsorption

(Moles
·mg−1 ). constant (polymer needed to achieve a half-maximum adsorption).
adsorption

3

NS is the slope of

nonspecific adsorption (Moles·mg ).
−1

2.4. Polymer Evaluation: Myographic Studies
2.4.The
Polymer
Evaluation:
Myographic
Studiesto ETA were evaluated using the myographic contractile
adsorption
properties
of polymers
response.
inhibition
curves
for MIPto
and
NIP
areevaluated
shown in using
Figurethe
5a.myographic
The smoothcontractile
muscle
TheStandard
adsorption
properties
of polymers
ETA
were
contraction
of saphenous
veins curves
decreased
in a dose
dependent
fashion
after 5a.
ETAThe
was
exposed
to
response. Standard
inhibition
for MIP
and NIP
are shown
in Figure
smooth
muscle
increasing
amounts
of each polymer
in the range
to 10 mg,
with ICafter
0.511was
and exposed
0.729 mgto
contraction
of saphenous
veins decreased
in afrom
dose0.625
dependent
fashion
50 ofETA
forincreasing
MIP andamounts
NIP, respectively.
However,
significant
(p 0.511
= 0.163)
IC50
of each polymer
in thethere
rangewas
fromno
0.625
to 10 mg,difference
with IC50 of
and in
0.729
mg
between
MIP
and
NIP.
Additionally,
there
was
no
difference
in
maximum
(p
=
0.96)
or
minimum
for MIP and NIP, respectively. However, there was no significant difference = 0.163) in IC50 between
(p MIP
= 0.26)
response there
between
(Table 3).
there was
no
andinhibitory
NIP. Additionally,
wasthe
no polymers
differencetested
in maximum
(p =Furthermore,
0.96) or minimum
(p = 0.26)
significant
difference
= 0.24) inthe
thepolymers
calculatedtested
area under
the3).inhibitory
response
curve
MIP
inhibitory
response(pbetween
(Table
Furthermore,
there
wasbetween
no significant
and
NIP (Figure
5b). in the calculated area under the inhibitory response curve between MIP and NIP
difference
(p = 0.24)
(Figure 5b).
Table 3. Maximum and minimum inhibition and IC50 for norepinephrine normalized contractile
response of saphenous veins exposed to ETA treated with MIP and NIP.
Polymers

Contractile Response
At maximum inhibition, %
At minimum inhibition, %
IC50 , mg of polymer

MIP

NIP

SEM

p-Value

9.1
88.0
0.51

9.2
70.0
0.73

1.79
10.92
0.105

0.96
0.26
0.16

Inhibitory concentration (IC50 ) values were calculated by a fitting concentration-response relationship to a sigmoidal
model of the form response vs log [inhibitor] (Equation (4), Section 5.7). The IC50 is the concentration of inhibitor
(polymer) in milligrams that produces a 50% response between maximum and minimum inhibition.
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Figure 5. (a) Effect of increasing doses of MIP and NIP on the NE-normalized contractile response of
Figure 5. (a) Effect of increasing doses of MIP and NIP on the
NE-normalized contractile response of
saphenous veins, induced by ETA (7.813 × 10−7 M)
in a 1 h, 39 ◦ C incubation. (b) T-test analysis of
saphenous veins, induced by ETA (7.813 × 10−7 M) in a 1 h, 39 °C incubation. (b) T-test analysis of area
area under the curve for comparison of MIP and NIP. Data are expressed as mean ± SEM (n = 12).
under the curve for comparison of MIP and NIP. Data are expressed as mean ± SEM (n = 12). Similar
Similar letters (a) above columns denote lack of significant difference (p > 0.05) between columns.
letters (a) above columns denote lack of significant difference (p > 0.05) between columns.
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Pre-incubation of ETA in medium containing increasing concentrations of MIP or NIP reduced
the contractile response in a dose dependent manner. To determine the biological implications of in
vitro adsorption efficiencies, the ex vivo myographic response observed for treatments was related
to adsorption efficiencies of polymers, obtained from in vitro studies. The predicted contractile
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for free [ETA] in isothermal adsorption studies were regressed against8 ofthe
measured myographic response (Figure 6a,b, Table 4). Results showed that the contractile response
for the polymers was predicted with a coefficient of determination of 0.82 and 0.87 for MIP and NIP,
for the polymers was predicted with a coefficient of determination of 0.82 and 0.87 for MIP and NIP,
respectively. Additionally, for both polymers, the slopes of the prediction lines did not differ (p >
respectively. Additionally, for both polymers, the slopes of the prediction lines did not differ (p > 0.05)
0.05) from 1 and the y-intercepts did not differ (p > 0.05) from 0.
from 1 and the y-intercepts did not differ (p > 0.05) from 0.
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Figure 6. Regression plot between the measured and the predicted percent contractile response
Figure 6. Regression plot between the measured and the predicted percent contractile response (NE(NE-normalized) in the presence of increasing concentrations of (a) molecularly imprinted polymer
normalized) in the presence of increasing concentrations of (a) molecularly imprinted polymer and
and (b) non-molecularly imprinted polymer. Dotted lines represent 95% confidence intervals. The
(b) non-molecularly imprinted polymer. Dotted lines represent 95% confidence intervals. The
residuals (c) MIP and (d) NIP are shown on the right side of the plot.
residuals (c) MIP and (d) NIP are shown on the right side of the plot.
Table 4. Regression equation and fit parameters for the prediction of the contractile response (Y)
Table 4. Regression equation and fit parameters for the prediction of the contractile response (Y) (NE(NE-normalized) of saphenous vein smooth muscles by ergotamine (x) in the presence of MIP and NIP.
normalized) of saphenous vein smooth muscles by ergotamine (x) in the presence of MIP and NIP.

Regression
Equation
Regression
Equation
MIP Y = 0.98
Y = 0.98
± 0.07(x)
+ 0.15±±2.07
2.07
MIP
± 0.07(x)
+ 0.15
NIP
Y = 0.92 ± 0.05(x) − 1.35 ± 1.75
NIP
Y = 0.92 ± 0.05(x) − 1.35 ± 1.75

2R2

R
0.82
0.82
0.87
0.87

95%CI
CI
95%
y-Intercept
y-Intercept
<0.01 0.850.85
to 1.12 −4.01
−4.01to
to 4.32
4.32
<0.01
to 1.12
<0.01
0.81 to 1.03
−4.87 to 2.17
<0.01
0.81 to 1.03 −4.87 to 2.17

p-Value
p-Value

Slope
Slope

3. Discussion
For grazing animals, one of the most important physiological effects of forage-associated alkaloid
consumption is vasoconstriction [5,6,38,39], mediated through effects on smooth muscle, especially
via serotonergic [4,42] and adrenergic [43] receptors. Thus, myographic analysis is a relevant tool
for assessing the potential value of alkaloid mitigation strategies. We previously developed and
characterized a pair of synthetic polymers (MIP and NIP) with demonstrated adsorptive characteristics
towards a variety of ergot alkaloids [41]. That work indicated that, in aqueous media, most
of the binding occurred through nonspecific interactions, resulting in little difference in binding
characteristics towards ETA between MIP and NIP. Evaluation in aqueous media was integral to the
present study, given the ultimate interest in the application of adsorbents as feed additives. Maintaining
specificity of adsorption in polar solvents is a known challenge with MIP, particularly because of
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the masking of hydrogen bonding effects important for the specificity of binding [44]. Nonetheless,
our previous work indicated comparatively high binding affinities of both of these products for the
alkaloid compounds of interest, when compared with other products that have been evaluated in the
literature [41]. Additionally, we determined substantial differences in the surface area and porosity of
the two products, which could have important effects on binding in different scenarios. The results from
the present study corroborated our previous work, in that the isothermal ETA binding characteristics
of MIP and NIP were similar to each other. Another goal of the present work was to establish the
validity of using simple isothermal adsorption characteristics to predict potential physiological effects
after adsorption. This relationship could be confounded by epimerization of ETA, which is influenced
by pH, heat and light, resulting in potential differences in the ratio of biologically active (R-) to inactive
(S-) forms of ETA [45–47]. Although isomeric ratios could be determined analytically (e.g., with
LC-MS/MS), extraction conditions (extraction solvents, pH, time of extraction, effects of heat and
temperature) would render interpretation challenging. Thus, we utilized a myographic bioassay
to determine whether adsorption of ETA onto our synthetic polymers resulted in a quantitatively
predictable effect on vasoconstriction.
The initial two validation studies evaluated the influence of incubation time and temperature
on the vasoconstrictive response to ETA, and the third validation study confirmed that there was no
non-specific binding to the filtration column that would influence the myographic response. Our
studies showed a decrease in the myographic response by nearly 25 percent due to incubation,
and the reduced contractile response could be due to isomerization to the less active form of the
molecule, ergotaminine. Therefore, a correction factor was used to estimate the free vasoactive ETA
concentrations following incubation. Additionally, the ETA stock solution was prepared using DMSO
to increase the solubility and reduce precipitation in buffer solution. DMSO was present in all the
samples in the same proportion.
Our myographic methodology differed somewhat from that of the prior studies which were used
to establish the range of ETA concentrations used here. In particular, in the previous studies, the
ETA agonist was added in a cumulative fashion to individual vessel sections to establish contractile
response curves [7,14]. To avoid potential carryover effects in the present experiment, we used single
doses of ETA at different concentrations on each blood vessel section to generate the dose response.
Although the shape of the binding curve and binding parameters measured in the present study were
similar to those reported for ergot alkaloid exposure in saphenous veins [14], mesenteric arteries and
veins [7], and ruminal arteries and veins [6], the lower standard errors in the present work were likely
related to this methodological difference.
Compound efficacies are commonly compared using the IC50 values, i.e., the inhibitory
concentration of the compound that decreases the agonist response by 50 percent [48,49]. The
in vitro isothermal adsorption study showed that the amounts of MIP and NIP required to reduce the
bioavailability of ETA by 50 percent (Kd values) were 0.51 and 0.57 mg, respectively. When comparing
the effect of these polymers in reducing saphenous vein smooth muscle contractions, the efficacies of
polymers to reduce the ETA-induced maximal response by 50 percent (IC50 ) were 0.51 and 0.73 mg for
MIP and NIP, respectively. Increasing the concentration of either polymer decreased the contractile
response, but there was no significant difference between MIP and NIP in reducing the bioavailability
of ETA. Although a high affinity of imprinted polymers compared to non-imprinted polymers towards
ergot alkaloids has been observed in solid phase extraction (SPE) applications with non-aqueous
solvent [50], our results revealed no significant differences for either affinity (Kd ) or the IC50 values
between imprinted and non-imprinted polymers.
Additionally, the measured concentration of ETA remaining after adsorption (i.e., bioavailable
concentration) was used to estimate the contractile response using the dose response curve
(Equation (3), Section 5.7). With the use of a constant adjustment factor (the 0.75 multiplier in
Equation (1), Section 2.5) to account for the systematically lowered contractile response attributed
to our incubation model (likely associated with epimerization), vasoconstriction was predicted with
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reasonable accuracy (R2 = 0.82 to 0.87) and without bias, for both MIP and NIP. These results indicate
that the parameters generated from in vitro studies to determine the efficacy of adsorbents can be
extrapolated to their physiological significance in biological systems.
The use of adsorbents to reduce ergot alkaloid bioavailability can be considered more beneficial
than strategies attempting to treat the symptoms of ergot alkaloid toxicity. Results of the present
study confirm other reports showing a direct relationship between the concentration of ETA and
the intensity of the corresponding contractile response of smooth muscles in blood vessels [6,7].
A prolonged and persistent contractile response is induced at low concentrations of ETA if the blood
vessel is exposed for an extended period of time [4,14], due to strong interactions with serotonin
receptors [5,42]. Additionally, ergopeptides, including ETA and ergovaline, have been shown to
interact with serotonergic receptors and myenteric neurons in the gut, affecting gut motility [51,52]
and the baseline tone and inhibition of ruminal or reticular contractions [13]. This sustained interaction
of ETA with receptors also creates an opportunity for ergot alkaloid accumulation, which may exceed
the rate of receptor recycling or turnover, causing greater impact on normal biological processes.
Bioaccumulation in lateral saphenous veins after repetitive exposure to ergovaline in vitro has been
suggested [53]. The potential for ergot alkaloid build-up in tissues of exposed animals could be
one factor behind the persistent contraction and delay in vascular recovery after removal of animals
from endophyte infected diets [54,55]. This prolonged stimulation of serotonin receptors may result
in receptor desensitization [56] or receptor internalization [57] which may lead to inefficiency with
treatments involving antagonistic mechanisms, especially receptor blockers. Therefore, feed additives
that reduce the available ergot alkaloids in the gut may provide better protection.
4. Conclusions
Ergotamine, along with other ergot alkaloids, can influence vascular smooth contraction of
bovine lateral saphenous veins. This study indicated that a pre-myograph incubation with MIP
or NIP at an inclusion rate between 0.625 and 10 mg per 7.81 × 10−7 M of ETA in 10-mL volume,
reduced the contractile response to ETA in lateral saphenous veins in a dose dependent fashion.
There were no indications that imprinted polymers were more effective in reducing the contractile
response compared to non-imprinted polymers, when evaluated in aqueous environments. The ex vivo
contractile response could be predicted from the in vitro adsorption data with more than 80% accuracy,
indicating the physiological significance of the isothermal adsorption parameters. These studies
indicate that synthetic polymers are potentially effective adsorbents to mitigate ergot toxicity caused by
ergot alkaloids with little evidence of significant differences between MIP and NIP. However, further
animal studies are required to assess the application of imprinted polymers as selective adsorbents of
ergot alkaloids in feed.
5. Materials and Methods
The procedures used in this study did not require approval from the University of Kentucky
Animal Care and Use Committee because the blood vessels were collected from animals designated
for slaughter in a local abattoir or the University of Kentucky Meats Laboratory.
5.1. Animals and Tissues
Experiments were conducted using the cranial branch of the lateral saphenous vein, which was
dissected from both hind limbs of mixed breed and gender cattle (n = 17; BW 572 ± 96 kg; 20–36
months) shortly after the animals were slaughtered (stunned with captive bolt and exsanguinated)
at the University of Kentucky or a local abattoir, in accordance with established procedures [38].
Excised tissue sections were placed in a modified Krebs–Henseleit oxygenated buffer (95% O2 +
5% CO2 ; pH = 7.4; mM composition = D-glucose, 11.1; MgSO4 , 1.2; KH2 PO4 , 1.2; KCl, 4.7; NaCl,
118.1; CaCl2 , 3.4; and NaHCO3 , 24.9; Sigma Chemical Co., St. Louis, MO, USA) that was cooled on
ice, and transported to the laboratory. Adipose and connective tissue surrounding the blood vessel
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was removed and the cleaned vessel was sliced into 2-mm cross-sections under a 12.5× magnifying
dissecting microscope (Stemi 2000-C; Carl Zeiss Inc., Oberkochen, Germany), without damaging the
endothelium. Before mounting the blood vessels in myograph chambers, the lumen, outer diameter
and width of the sections were measured under a light microscope to confirm structural integrity and
consistent dimensions across sections (Axiovision, version 20, 2017; Carl Zeiss Inc., Jena, Germany).
5.2. Dose Response to ETA
Dose response curves were generated by exposing blood vessels to increasing concentrations
of ETA. A stock solution of 20 mM ETA was prepared (11.63 mg/mL DMSO; MW: 581.66, ≥ 97%
purity, #45510, Fluka, Sigma Chemical Co.) and aliquoted in 100-µL volumes into silanized HPLC
vials and stored at −20 ◦ C until use. A diluting buffer was prepared by adding 500 µL of DMSO to
99.5 mL of modified Krebs–Henseleit buffer. An ergotamine working solution of 1.000 × 10−3 M was
prepared by adding 100-µL volume of stock solution to 19.90 mL of diluting solvent. Subsequently, ten
serial dilutions (1:1) were made using the diluting solution to yield working solutions of 5.000 × 10−5 ,
2.500 × 10−5 , 1.250 × 10−5 , 6.250 × 10−6 , 3.125 × 10−6 , 1.563 × 10−6 , 7.813 × 10−7 , 3.906 × 10−7 ,
1.953 × 10−7 and 9.766 × 10−8 M, and a control of 0.00 M ETA and a 5-mL aliquot was added to the
myograph chamber and incubated for 1 hr at 39 ◦ C. No buffer replacement occurred during this 1-hr
incubation period and each blood vessel cross-section was only exposed to a single ETA concentration.
At the end of the incubation period, an aliquot of norepinephrine (500 µL, 1 × 10−4 M) was added to
confirm tissue viability.
5.3. Validation Studies
An ergotamine concentration of 7.81 × 10−7 M that represented the 75th percentile contractile
response from the dose response curve was chosen for all the polymer adsorption studies. The 75th
percentile was chosen to ensure that the treatment ETA concentrations, after the addition of polymers,
produced a contractile response in the linear range of the sigmoidal dose response curve. Additionally,
for accuracy and reliability, the isothermal adsorption conditions, including incubation time (2 min
vs. 60 min), temperature during adsorption (39 vs. 21 ◦ C) and non-specific binding (with or without
filtration column), that would possibly affect myographic results, were examined and validated.
5.4. Polymer Evaluation: Isothermal Adsorption Studies
Methacrylic acid-based polymer adsorbents were synthesized, in accordance with a previously
published protocol [40,41]. Briefly, bulk polymerization with self-assembly was used in the synthesis
of polymers. During the synthesis of MIP, NIP without template was synthesized using the same
protocol. Ergotamine tartrate (5.00 × 10−3 mol), methacrylic acid (MAA) (8.00 × 10−2 mol) and
hydroxyethyl methacrylate (HEMA) (4.00 × 10−2 mol) were dissolved in 10 mL toluene in a 250-mL
round bottom flask and purged with high-purity dry nitrogen for 30 min at room temperature.
Following the incubation period, ethylene glycol dimethacrylate (EGDMA) (4.00 × 10−1 mol),
2,2-azobisisobutyronitrile (AIBN) (4.00 × 10−3 mol) and toluene (65 mL) were added. Polymerization
was initiated by placing the reaction mixture in an oil bath set at 65 ◦ C and propagated for 5-h with
stirring. Polymerization was terminated by reducing the temperature to 22 ◦ C. The mixture was then
filtered and the pellet was subjected to a template removal procedure using acidic methanol (0.2 N
HCL in methanol (100 mL, 5 times) and acetonitrile (100 mL, 5 times). The polymer products were
freeze-dried overnight and oven-dried (60 ◦ C for 24 h) before being used in the study.
Isothermal adsorption studies were validated for inclusion rates of polymer that would generate
a dose response curve showing affinity and saturation. Two independent studies were conducted, with
inclusion rates between 0.001 and 10 mg in log10 scale and between 0 and 10 mg in log2 scale. Responses
from the log2 scale yielded a better curve fit, so this scale was used for all polymer evaluations with the
myographic studies. Six inclusion levels of polymer were prepared by weighing 0, 0.625, 1.25, 2.5, 5 and
10 mg of MIP or NIP in 30-mL silanized amber color bottles, in duplicate. An ETA working solution was
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prepared by adding 4.68 µL of stock solution into 120 mL Krebs–Henseleit incubation buffer, yielding
7.813 × 10−7 M concentration. A 10 mL volume of ETA working solution (7.813 × 10−7 M) was added
to each bottle containing different polymer masses and incubated for 15 min with shaking. The solution
was then filtered using a solid phase extraction cartridge (SPE) to separate the polymer-ETA complex
from free ETA, and a 5 mL aliquot of the filtrate was placed in a water bath for 15 min to reach a
temperature of 39 ◦ C. The treatments were added to the myographic chambers and incubated for 1 h at
39 ◦ C. At the end of the incubation period, norepinephrine (500-µL, 1 × 10−4 M) was added to confirm
tissue viability. Each myograph chamber received only one treatment and treatment concentrations
were administered in duplicate within each animal. Additionally, to determine adsorption efficiency,
an aliquot of 1 mL from filtrate was collected in a silanized amber HPLC vial and analyzed for ETA
concentrations by HPLC-fluorescence.
5.5. Myograph Experiments
Prior to mounting blood vessels, 12 myograph chambers (MT610M, Danish Myo Technologies,
Atlanta, GA, USA) were calibrated for tension with 2-g calibrated weights. Blood vessel segments were
individually mounted on calibrated luminal supports in separate myograph chambers and equilibrated
in 5-mL of modified Krebs–Henseleit (37 ◦ C) containing desipramine (3.00 × 10−5 M; D3900 Sigma
Chemical Co.) and propranolol (1.00 × 10−6 M; P0844, Sigma Chemical Co., St. Louis, MO, USA) to
inactivate neuronal uptake of catecholamines and to block β-adrenergic receptors, respectively [38].
The buffer solution was replaced at 15 min intervals throughout the equilibration period, for 90 min,
to achieve a baseline tension of 1 g. Norepinephrine (500-µL, 1.00 × 10−4 M) was added to check
the viability of the tissue and for subsequent normalization of the tissue response data. Before the
addition of test samples, blood vessels were returned to a baseline tension of 1 g by washing with
modified Krebs–Henseleit buffer at 15-min intervals. The maximum tension observed during a 60-min
incubation period after the addition of a treatment was recorded and corrected for baseline tension,
measured just before the addition of the treatment.
5.6. HPLC Analysis of ETA
A series 2695 Alliance HPLC separation module (Waters, Milford, MI, USA), equipped with a
binary pump, an auto sampler, a column oven and a fluorescence detector (474 scanning fluorescence
detector, λex 250 nm, λem of 420 nm, gain 16 and attenuation 1000) was used to analyze ergot alkloids
in the samples. Chromatographic data were integrated using Waters Empower 3 software 7.00.00.99
(Waters, Milford, MI, USA). HPLC separations were performed with a 100 × 4.6 mm i.d., 2.6 µm
particle size, Kinetex C18 column (Phenomenex, Torrance, CA, USA) with a gradient elution consisting
of two mobile phases, (A) water and (B) acetonitrile, both spiked with ammonium hydroxide (0.04%).
Initial gradient conditions were 100% A, held for 1 min, increasing linearly to 100% B over 12 min and
held for 3 min. Finally, a linear return to initial conditions over 3 min was held for 2 min for a total run
time of 21 min. The sample injection volume was 50 µL. Samples were evaporated to near dryness and
the residues dissolved in methanol/water (50/50) and analyzed [34].
5.7. Data and Statistical Analyses
The myographic contractile response was recorded at the end of the incubation period, as g of
tension, using 16/35 Powerlab and Chart software (Version 8.1.3, 2016; AD Instruments, Colorado
Springs, CO, USA). The data were normalized to the maximum contractile response of norepinephrine
from the same tissue (Equation (2)), to minimize animal to animal variations and differences in
contractile response magnitudes due to different sized veins [38].
Percent contraction = [sample response (Max − Min)/NE response (Max − Min)] × 100

(2)
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The minimum and maximum responses of each sample represent the myographic readings
(tension in smooth muscle, g), before and after addition of treatment, respectively. For dose response
curves, a non-linear standard curve was established by plotting the normalized contractile response
against the concentration of ETA, i.e., response vs log [agonist] (Equation (3)).
Y = Min + (Min − Max)/(1 + 10(LogEC50−X) )

(3)

The EC50 (effective concentration) is the concentration of agonist that gives a response half way
between the minimum (low contractile response) and maximum (high contractile response), expressed
in percent.
To determine the ability of a polymer to reduce the contractile response, the NE-normalized
percent contraction of smooth muscle to ETA was fitted against the polymer levels in the media, i.e.,
response vs log [inhibitor] (Equation (4)).
Y = Min + (Max − Min)/(1 + 10(X-LogIC50) )

(4)

Maximum (Max) and minimum (Min) are plateaus in the units of the % contraction (NE
normalized) and IC50 (inhibitory concentration) is the concentration of polymer (mg) that is halfway
between maximum and minimum inhibition.
The isothermal adsorption efficiency of polymers to ETA in buffer media was determined using
Equation (5) with GraphPad Prism Software, version 5.01 (GraphPad Software 2007, San Diego,
CA, USA).
Amount adsorbed (moles·mg−1 ) = (Bmax × X)/(Kd + X) + NS × X
(5)
where, Bmax is the maximum specific adsorption (moles·specific weight of polymer−1 ), Kd is the
equilibrium adsorption constant (mg of polymer), indicating the amount of polymer needed to achieve
a half-maximum adsorption at equilibrium and NS is the slope of nonspecific adsorption (moles·mg−1 ).
The percent contractile responses of ETA after the 60-min incubation period were compared
between the polymer types. The experimental model used was a completely randomized design
and data were analyzed using the mixed procedure of SAS (version 9.2; SAS Inst. Inc., Cary, NC,
USA), considering the effect of treatment as a fixed effect, with vein cross-sections serving as the
experimental unit. Values are shown as mean ± SEM. Concentration–response curves were fitted by
nonlinear regression using response vs log [agonist], and a nonlinear regression of response vs log
[inhibitor] was used for polymer evaluation. Statistical analyses for nonlinear fit parameters and for
agonist or inhibitor effects on smooth muscle contraction involved simple t-tests using GraphPad
Prism Software, version 5.01 (GraphPad Software 2007, CA, USA). Non-normally distributed data
analyses were conducted with non-parametric t-tests, followed by the Mann–Whitney test. Differences
between means were declared significant for p-values lower than 0.05 (in two-tailed tests).
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